Date: 2015-08-04
Type of
information: update on patient enrollment
phase: 2
Announcement:
Company: Retrophin (USA - CA)
Product: sparsentan (RE-021)
Action
mechanism:
- endothelin receptor antagonist/angiotensin receptor blocker. Sparsentan has two separate mechanisms of action, acting as both an Endothelin Receptor Antagonist (ERA) and Angiotensin Receptor Blocker (ARB). Studies in similar nephropathies have shown ERAs and ARBs to both be effective in reducing proteinuria.
- Ligand Pharmaceuticals licensed worldwide rights of sparsentan (RE-021) (formerly known as DARA) to Retrophin in 2012, at the time of Retrophin’s formation.
Disease: focal segmental glomerulosclerosis
Therapeutic
area: Rare diseases
Country: Belgium, Czech Republic, Italy, USA
Trial
details:
- This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1), is safe and effective in treating patients with focal segmental glomerulosclerosis (FSGS). (NCT01613118)
Latest
news:
- • On August 4, 2015, Retrophin announced that The Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS) continues to enroll toward the target of 100 patients by year-end 2015
Is
general: Yes
